Metastatic TNBC has an urgent need for new therapies that can boost outcomes in patients. Credit: Ewa Krawczyk, National Cancer Institute Georgetown Lombardi Comprehensive Cancer Center, National Institutes of Health / Flickr.

Gilead Sciences and Merck (MSD) have signed a clinical trial partnership and supply agreement to assess the efficacy of the former’s Trodelvy (sacituzumab govitecan-hziy) along with the latter’s Keytruda (pembrolizumab) to treat triple-negative breast cancer (TNBC).

The combination treatment will be analysed as first-line therapy for locally advanced or metastatic TNBC patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Trodelvy is a conjugate of antibody and topoisomerase inhibitor that directly acts on the Trop-2 receptor while Keytruda is an anti-programmed cell death protein 1 (PD1) therapy.

Trop-2 is a protein overexpressed in various epithelial tumour types.

Trodelvy acts on Trop-2 expressing cells to facilitate the local delivery of a cytotoxic payload that specifically destroys the targeted cells.

According to the deal, Gilead will fund an international Phase III trial of the combination therapy.

The trial will analyse Trodelvy plus Keytruda as against the standard of care comprising Keytruda plus chemotherapy in first-line subjects with locally advanced or metastatic TNBC.

Gilead Sciences chief medical officer Merdad Parsey said: “Trodelvy has already been established as a preferred treatment option in second-line metastatic TNBC.

“Looking ahead, we are excited about the opportunity to advance Trodelvy as a potential treatment for first-line metastatic TNBC. This helps further our ambition of displacing chemotherapy with Trodelvy to improve outcomes for people living with cancer.”

With the lowest survival rate among various other types of breast cancer, metastatic TNBC has an urgent need for novel treatments that can boost outcomes in patients.

Combining Trodelvy with an immune-stimulating drug such as Keytruda might potentially offer a new treatment for first-line metastatic TNBC, Gilead noted.

Trodelvy plus Keytruda is currently not approved by any regulatory authorities in any therapy setting with the safety and efficacy of the combination still being analysed.

In March, Merck and Gilead signed a deal to co-develop and co-commercialise long-acting HIV treatments.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.